泰达生物(08189)发布中期业绩 股东应占亏损642.64万元 同比扩大55.86%

Group 1 - The core viewpoint of the article is that Teda Bio (08189) reported its interim results for the six months ending June 30, 2025, showing a revenue of RMB 226 million, which represents a year-on-year growth of 7.01% [1] - The company experienced a loss attributable to shareholders of RMB 6.4264 million, which is an increase of 55.86% compared to the previous year [1] - The loss per share is reported at 0.317 cents [1]